Vascular endothelial growth factor-C secretion is increased by advanced glycation end-products: Possible implication in ocular neovascularization

Molecular Vision

Volumn 18, Issue , 2012, Pages 2509-2517

  Puddu, Alessandra ^a   Sanguineti, Roberta ^a   Durante, Arianna ^a   Nicolò, Massimo ^a   Viviani, Giorgio L ^a  

^a Department of Internal Medicine and Medical Specialties ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; MESSENGER RNA; VASCULOTROPIN A; VASCULOTROPIN C;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR PATHOLOGY; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN SECRETION; RETINA NEOVASCULARIZATION; VASCULOTROPIN C GENE;

ANTIBODIES, MONOCLONAL, HUMANIZED; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, IMMUNOLOGIC; RETINAL PIGMENT EPITHELIUM; RNA, MESSENGER; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84868134298     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580:2879-87. [PMID: 16631753].
2. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29. [PMID: 12597922].
3. Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett 2006; 580:2879-87. [PMID: 16631753].
4. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29. [PMID: 12597922].
5. Young TA, Wang H, Munk S, Hammoudi DS, Young DS, Mandelcorn MS, Whiteside CI. Vascular endothelial growth factor expression and secretion by retinal pigment epithelial cells in high glucose and hypoxia is protein kinase C-dependent. Exp Eye Res 2005; 80:651-62. [PMID: 15862172].
6. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br J Ophthalmol 2007; 91:1318-22. [PMID: 17537784].
7. Bopp S. Anti-VEGF for neovascular ARMD: visual improvement as the goal of therapy? Br J Ophthalmol 2007; 91:1259-60. [PMID: 17895411].
8. Arias L, Caminal JM, Badia MB, Rubio MJ, Catala J, Pujol O. Intravitreal infliximab in patients with macular degeneration who are nonresponders to antivascular endothelial growth factor therapy. Retina 2010; 30:1601-8. [PMID: 21060271].
9. Abdullah SE, Perez-Soler R. Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer 2012; 118:3455-67. [PMID: 22086782].
10. Schwartz SG, Flynn HW Jr, Scott IU. Pharmacotherapy for diabetic retinopathy. Expert Opin Pharmacother 2009; 10:1123-31. [PMID: 19405788].